Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia

Inhibitors of the phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) pathway are currently in clinical trials. In addition to antiproliferative and proapoptotic effects, these agents also diminish tumor hypoxia. Since hypoxia is a major cause of resistance to radiother...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Radiotherapy and oncology Jg. 111; H. 1; S. 72 - 80
Hauptverfasser:	Kelly, Catherine J., Hussien, Kamila, Fokas, Emmanouil, Kannan, Pavitra, Shipley, Rebecca J., Ashton, Thomas M., Stratford, Michael, Pearson, Natalie, Muschel, Ruth J.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Ireland Elsevier Ireland Ltd 01.04.2014 Elsevier Scientific Publishers
Schlagworte:	Aminopyridines - pharmacology Animals Cell Hypoxia - drug effects Cell Hypoxia - physiology Cell Line, Tumor HCT116 Cells Hematology, Oncology and Palliative Medicine Humans Hypoxia Imidazoles - pharmacology Mice Molecular Radiobiology Morpholines - pharmacology mTOR Neoplasms - enzymology Neoplasms - metabolism Oxidative metabolism Oxygen Consumption - physiology Phosphatidylinositol 3-Kinase - metabolism Phosphoinositide-3 Kinase Inhibitors PI3K Protein Kinase Inhibitors - pharmacology Quinolines - pharmacology Reoxygenation Signal Transduction - drug effects Spheroids, Cellular TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism mTOR Hypoxia PI3K Reoxygenation Oxidative metabolism
ISSN:	0167-8140, 1879-0887, 1879-0887
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!